Elicio Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Elicio Therapeutics, Inc. (ELTX) on June 27, 2024. The filing discloses preliminary disease-free survival (DFS) analysis from the ongoing AMPLIFY-7P Phase 1a study of the investigational therapeutic cancer vaccine candidate, ELI-002 7P. The study targets patients with mutated Kirsten rat sarcoma viral oncogene homolog (mKRAS)-driven solid tumors.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and regulatory disclosures.
Material Changes and Clinical Data
The primary material event is the release of preliminary data from the AMPLIFY-7P Phase 1a study as of a May 24, 2024 data cutoff (14 patients enrolled):
- Median DFS (4.9 mg dose): Not reached for the 8 patients receiving the Phase 2 dose of 4.9 mg AMP-peptide.
- Median DFS (1.4 mg dose): 12.6 weeks for the 6 patients receiving the 1.4 mg AMP-peptide dose.
- Median Follow-up: 29.1 weeks for the DFS endpoint.
- Biomarker Response: Patients with reduced tumor biomarker levels experienced no progression events, compared to a median DFS of 11.0 weeks for non-responders.
- T Cell Response: Patients with an above-median T cell response had no progression events as of the data cutoff.
Guidance, Outlook, and Risks
The Company continues to evaluate the safety and efficacy of ELI-002 7P as an adjuvant monotherapy. The data suggests a potential correlation between higher peptide doses, biomarker reduction, T cell response, and improved disease-free survival. No specific financial guidance or forward-looking revenue projections were included in this filing. Standard risks associated with clinical development, including the possibility that preliminary data may not be replicated in larger trials, apply.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis and confidence intervals.
- Review the updated corporate presentation (Exhibit 99.2) for broader strategic context and pipeline updates.
- Confirm the enrollment status and timeline for the Phase 2 portion of the AMPLIFY-7P trial.
- Monitor future filings for updated safety data and long-term efficacy results beyond the 29.1-week follow-up period.